| abstract |
REFERS TO COMPOUNDS OF FORMULA (I) WHERE Q IS OR U S; X IS CR3 O N; W IS C O N; V IS CR2, O U S; L1 IS CR9 O N, WHERE R2, R3, R7 AND R9 ARE EACH H, ALKYL (C1-C10), ALKENYL (C2-C6), ALCOXY (C1-C10), CYCLOALKYL (C3-C10), AMONG OTHERS; L2 IS CR6 O N, WHERE R4, R5 AND R6 ARE EACH H, HALOGEN, CN, NITRO, AMINO, AMONG OTHERS; R1 IS H, ALKYL (C1-C10), ALCOXY (C1-C10), ARIL (C6-C14), CYCLALKYL (C3-C10), AMONG OTHERS; R8 IS H, ALKYL (C1-C10), CYCLOALKYL (C3-C7), AMONG OTHERS. PREFERRED COMPOUNDS ARE: N- (6- (6-AMINO-5- (TRIFLUOROMETHYL) PYRIDIN-3-IL) IMIDAZO [1.2-b] PYRIDAZIN-2-IL) ACETAMIDE, METHYL 6- (6-AMINO-5- ( TRIFLUOROMETIL) PYRIDIN-3-IL) IMIDAZO [1.2-a] PYRIDIN-2-ILCARBAMATE, N- (6- (6-AMINO-5- (TRIFLUOROMETIL) PYRIDIN-3-IL) -3-BROMO-IMIDAZO [1.2- a] PYRIDIN-2-IL) ACETAMIDE, AMONG OTHERS. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID COMPOUNDS ARE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) BEING USEFUL IN THE TREATMENT OF GLIOMA, MELANOMA, ASTHMA, PULMONARY FIBROSIS, PSORIASIS, DERMATITIS |